ppi targeting

Ravidasvir, also known as PPI-668 and ASC16, is a second-generation oral medication that exhibits potent and selective inhibition specifically targeting the nonstructural protein 5A (NS5A) of the Hepatitis C virus (HCV).

AKCI is a PPI inhibitor that acts by targeting the AURKC-IκBα interaction.

M2I-1 a small Mad2 inhibitor-1. the first small molecule inhibitor targeting the binding of Mad2 to Cdc20, an essential proteinprotein interaction (PPI) within the SAC. It can disturbs conformational dynamics of Mad2 critical for complex formation with Cd

Efzimfotase alfa is an enzyme replacement therapy targeting tissue non-specific alkaline phosphatase (TNSALP) deficiency. By hydrolyzing substrates of TNSALP, Efzimfotase alfa reduces concentrations of substrates such as inorganic pyrophosphate (PPi) and pyridoxal 5'-phosphate (PLP). It is being investigated for its potential use in hypophosphatasia (HPP).